Quantum-Si incorporated (QSI)
Healthcare
- Fundamental
- 1
- Sentiment
- 2
- Technical
- 2
Do Nothing: fundamentalScore 1 and qualitativeScore 2 are both below the required floor of 3 (hard block; rendered shadow flag false so no compensation path), and the max overnight gap of 6.72% over the last 3 regular sessions exceeds the 5% limit so the protective stop could not cover off-hours repricing.
Company overview
Quantum-Si Incorporated develops a platform for single molecule detection in the life sciences sector. The company's technology focuses on proteomics, utilizing semiconductor advancements for next-generation protein sequencing. Founded in 2013, it is headquartered in Guilford, Connecticut.
Fundamental
very weakQuantum-Si's fundamentals are speculative with significant cash burn and dependency on future equity issuance.
Quantum-Si is a pre-commercial proteomics company: trailing revenue of about $1.3 million against an $85 million trailing net loss, revenue down roughly 59% year over year as customers wait for the Proteus platform launch now slated for Q2 2027. The balance sheet is genuinely clean — no debt and $149.4 million of cash and marketable securities with runway guided into Q4 2028 — but burn remains $65-90 million a year, further equity issuance is likely, share count has expanded about 55% in three years, and the discounted-cash-flow models imply downside of 91-101% versus the $1.15 share price. Speculative and not investment-worthy on fundamentals; the only thing to watch is the Proteus launch and the burn rate into it.
Sentiment
weakSentiment is mildly negative following a revenue miss and delayed product launch.
Dominant driver is the Q3 2026 print on 2026-11-05 (announced) — an EPS beat of roughly two cents funded by cost cuts, against a revenue miss and year-over-year revenue decline, with the Proteus commercial launch now framed for Q2 2027 — which turned a determinate sentiment delta from a bullish +0.35 baseline to a mildly negative −0.07 scoring window (≈ −0.42 deterioration), with no forward-dated catalyst inside 30 days and retail sentiment unmeasurable (Reddit 403 on both query attempts). The Red-Flag Screen is clean of severe and moderate caps; the setup is post-earnings digestion with no market-rewarded bullish leg to offset the negative reception.
Technical
weakTechnicals suggest a potential oversold bounce, but no confirmed bullish trend.
Short-term chart is mixed-to-weak and bounce-only. The last analyzed bar (2026-11-13) closed 1.15, below SMA20 1.34, EMA9 1.27, EMA21 1.29, WMA9 1.25, WMA21 1.33, DEMA14 1.27, TEMA14 1.20 and the daily VWAP 1.1875, but marginally above the rising SMA50 1.14 and comfortably above the SMA200 0.96 after a ~36% retrace from the 2026-10-29 high of 1.81. Momentum: RSI14 44.80 (neutral), Williams %R -90.41 (oversold), MACD line 0.01 vs signal 0.05 with histogram -0.04 (positive but fading for five sessions), and ADX14 22.55 falling from 38.48 on 2026-11-02 — the prior advance has lost conviction and the current leg prints lower highs (1.81 to 1.50 to 1.45 to 1.25 to 1.23). Volatility is extreme (ATR14 0.16 = 13.9% of price, StdDev20 0.18). Volume is thinning (20-day average dollar volume $10.42M but last three regular sessions average roughly $6.0M, with the heaviest recent session a down day). Constructive reads are limited to SMA50/SMA200 support beneath price and an oversold Williams %R; no confirmed bullish reversal.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

